The DNAH5 Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-edited pool of human lung carcinoma cells with targeted disruption of the DNAH5 gene. This polyclonal knockout population serves as a reliable loss-of-function model, providing a genetic tool for dissecting DNAH5-dependent processes. The bulk-edited format avoids clonal artifacts and retains population-level responses, making it suitable for robust downstream assays.
The parental NCI-H1299 cell line is a non-small cell lung cancer line derived from a lymph node metastasis. Widely used in cancer biology and drug screening, these cells offer a relevant epithelial context for studying ciliary biology, as they can be induced to form motile cilia under specific culture conditions such as air-liquid interface.
DNAH5 encodes axonemal dynein heavy chain 5, a core component of outer dynein arms essential for ciliary motility. Transcriptionally regulated by ciliogenic factors FOXJ1, RFX2, and RFX3, the DNAH5 protein assembles into dynein complexes alongside DNAI1, DNAI2, DNAL1, and assembly cofactors ODAD1, ODAD2, and CCDC103. Knockout of DNAH5 disrupts outer dynein arm formation, impairing ciliary beat generation, mucociliary clearance, and airway fluid flow.
In the context of NCI-H1299 cells, DNAH5 ablation creates a model to explore how motile cilia dysfunction intersects with lung carcinoma biology. This system permits investigation of primary ciliary dyskinesia-related pathways and Kartagener syndrome, while also enabling studies on the potential role of ciliary motility in cancer cell behavior and metastasis.
Researchers can apply this knockout model in a range of applications: modeling primary ciliary dyskinesia and other ciliopathies, respiratory disease research, ciliary beat frequency measurements via high-speed video microscopy, and evaluating mucociliary transport using air-liquid interface cultures. Standard validation includes Western blotting for DNAH5, immunofluorescence for ciliary localization, and RT-qPCR for ciliary gene expression. The cells are suitable for drug screens targeting ciliary defects. For further details, please contact Ascent Research.
